How is Rybelsus used for weight loss

Are you looking for a pill that can help you lose weight without injections? If so, you might be interested in Rybelsus, a game-changing oral medication that contains semaglutide, the same active ingredient as Wegovy, one of the most effective weight loss drugs on the market.

Rybelsus was originally approved for type 2 diabetes, but did you know that it has also shown impressive results for weight loss in both diabetic and non-diabetic people? In fact, some studies on the efficacy of Rybelsus for weight loss suggest that Rybelsus in non-diabetic patients can even outperform some of the injectable options, such as Wegovy and Mounjaro.

But how does Rybelsus work for weight loss? Can you take Rybelsus if you are not diabetic? If yes, how much weight can you lose on Rybelsus? In this article, we will delve into these queries and more. We will also review the latest research and evidence on Rybelsus and weight management. By the end of this article, you will have a better idea of whether Rybelsus is the right choice for you and how to use it safely and effectively.

Revolutionizing Weight Loss – How Does Rybelsus Work?

Obesity is a rapidly growing health concern worldwide, with its prevalence having nearly tripled since 1975. In 2016, there were over 1.9 billion overweight adults, including 650 million who were obese. This accounts for 39% of adults being overweight and 13% obese globally. Alarmingly, this trend is increasing among children and adolescents too. Being obese heightens the risk of serious health issues such as heart disease, diabetes, certain cancers, and joint problems. ¹ This highlights the importance of maintaining a healthy body weight.

Rybelsus, initially developed for diabetes, is emerging as a viable weight loss medication. Rybelsus weight loss in non diabetic patients: it aids in weight loss not only for diabetic patients but also for those who are overweight without diabetes.

What Is Rybelsus?

Glucagon-like peptide-1 (GLP-1) is a hormone produced by the body which aids in insulin production and blood sugar regulation. It also helps control appetite by slowing down the digestion process that contributes to weight loss. ²

Rybelsus, a medication for managing type 2 diabetes, includes semaglutide, a compound that acts similarly to GLP-1. This helps not only in managing diabetes by lowering blood sugar levels but also in supporting weight loss and maintenance. ^3,4

Semaglutide is available in various forms, primarily as injections, but Rybelsus is unique as it is the first FDA-approved oral medication with GLP-1-like action. Typically, the treatment begins with a dose of 3 mg that is increased over time, increasing to 7 mg after a month. It’s advised to take Rybelsus daily on an empty stomach. ^4,5

Does Rybelsus Cause Weight Loss?

Yes, Rybelsus causes weight loss by affecting several processes in the body relating to appetite suppression and blood sugar control.

How Does Rybelsus Work for Weight Loss?

Rybelsus, a pill form of semaglutide, helps with weight loss by acting like a natural body hormone called GLP-1. This hormone lowers blood sugar in several ways: it boosts insulin production from the pancreas, decreases the release of another hormone called glucagon, and slows down food digestion. Slower digestion makes you feel fuller for longer, which can lead to eating less and losing weight. ⁶

It also targets the brain’s area responsible for controlling hunger and fullness. It activates hormones that reduce the sensation of hunger and prolong the feeling of fullness after eating. This not only helps in reducing the urge to eat but also contributes to a higher metabolic rate, which is crucial for burning more calories throughout the day and achieving greater weight loss. ⁷

Is Rybelsus Approved for Weight Loss?

Rybelsus is not currently approved by the FDA specifically for weight loss. It is primarily approved for treating type 2 diabetes mellitus and is used off-label for weight loss.

However, Rybelsus is expected to be approved for weight loss soon.

Results With Rybelsus – How Quickly Can You Lose Weight on Rybelsus?

The effectiveness of Rybelsus for weight loss can be observed as early as 26 weeks, with more significant results appearing over a period of 68 weeks or longer. It demonstrates a progressive and effective timeline for weight loss in various clinical studies, however, individual results may vary.

1. 26 Weeks: According to one study, a daily oral dose of 10 mg leads to an average weight loss of about 10.6 pounds (4.8 kg) over a 26-week period, which is comparable to the average weight loss of 14.1 lb (6.4 kg) with 1-mg weekly subcutaneous dosing of semaglutide​​. ⁸
2. 68 Weeks (OASIS 1 Trial): Another study reported that Average weight loss exceeds 17% of body weight, with 40% of participants losing 20% or more after 68 weeks. This study also indicated that Rybelsus was more successful in causing significant weight loss compared to liraglutide (Victoza)​​. ⁹
3. 6 Months: in a 6-month study, A daily dose of 7 mg resulted in about 5 pounds loss, and 14 mg led to around 9 pounds loss. ¹⁰

Weight Loss in Non-Diabetic Patients – Can You Take Rybelsus If You Are Not Diabetic?

Rybelsus for weight loss in non-diabetic individuals, who are overweight or obese, has shown significant effectiveness as revealed by several studies.

1. Study on Patients with Cardiovascular Disease: Found that semaglutide was better than a placebo in reducing weight for patients with cardiovascular disease who were overweight or obese but not diabetic. ¹¹
2. Analysis of Multiple Trials: Data from four trials involving over 3,600 non-diabetic, obese individuals showed significant weight reduction with semaglutide. ¹²
3. Randomized Controlled Trial: A study involving overweight or obese adults without diabetes demonstrated that semaglutide, combined with diet and exercise, effectively led to weight loss. ¹³
4. Long-term Effectiveness: Over 68 weeks, semaglutide users saw an average weight reduction of 14.9% compared to 2.4% in the placebo group, indicating significant benefits over the long term. ¹⁴
5. Oral Semaglutide Study: Research showed that taking oral semaglutide led to a notable decrease in body weight compared to a placebo in non-diabetic adults. ¹⁵

How Much Weight Can You Lose on Rybelsus?

Rybelsus has shown significant effectiveness in weight loss. It can lead to an average weight loss of around 10-15% in both diabetic and non-diabetic individuals.

• PIONEER PLUS Trial (Diabetic Patients): Higher doses (25 mg and 50 mg) led to substantial weight loss. Specifically, the 50 mg dose resulted in an average loss of 10% of body weight, with over 60% of participants losing at least 5% of their body weight with a reduction in waist circumference over the course of the trial. ¹⁶
• Systematic Review and Meta-Analysis (Non-diabetic Individuals): This study, involving over 4,500 non-diabetics, showed an average weight reduction of around 10.09% (10.54 kg) with semaglutide compared to a placebo. It also led to decreases in BMI and waist circumference. ¹⁷

Rybelsus is effective in significantly reducing body weight, with the amount of weight loss being dependent on the dose. Higher doses of Rybelsus lead to greater weight loss.

Key Takeaways

• Rybelsus can lead to an average weight loss of about 10-15% in both diabetic and non-diabetic individuals.
• Significant weight loss is observed as early as 26 weeks, with more pronounced results over 68 weeks.
• Notable decreases in BMI and waist circumference are observed with Rybelsus.
• Consistent weight loss effects are observed over extended periods, up to 68 weeks.
• Rybelsus for weight loss in non-diabetic patients may improve blood sugar levels and metabolic health too.

FAQs

1. How long does it take to see results with Rybelsus?

Individual responses may vary, but some users may start noticing changes in weight over a few weeks to months. It’s crucial to maintain regular usage and follow your healthcare provider’s guidance for accurate results.

2. Can Rybelsus be used in combination with other weight-loss medications?

Rybelsus should not be combined with other GLP-1 receptor agonists or insulin and combining Rybelsus with other weight loss medications should be done under the supervision of a healthcare professional.

3. Are there any dietary restrictions while taking Rybelsus?

No specific dietary restrictions are associated with Rybelsus, but maintaining a balanced diet is essential for overall health. Consult with your healthcare provider for personalized dietary recommendations based on your specific health needs.

4. What should I do if I miss a dose?

If you miss a dose of Rybelsus, take it as soon as you remember. However, if it’s close to your next scheduled dose, skip the missed one and continue with your regular dosing schedule. Also, avoid doubling up on doses to make up for a missed one. If you have concerns or questions, consult your healthcare provider.

Bibliography

1. World Health Organization. (n.d.). Obesity and overweight. Retrieved from https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
2. Nauck, M. A., & Meier, J. J. (2014). Regulation of glucose homeostasis by GLP-1. Progress in Molecular Biology and Translational Science, 121, 23-65. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4159612/
3. Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., … & Garvey, W. T. (2021). Semaglutide for the treatment of type 2 diabetes mellitus. The New England Journal of Medicine, 384(20), 1975-1985. Retrieved from https://pubmed.ncbi.nlm.nih.gov/33964002/
4. American Diabetes Association. (2019). Oral Semaglutide for Type 2 Diabetes. Clinical Diabetes, 38(1). Retrieved from https://diabetesjournals.org/clinical/article/38/1/109/32187/Oral-Semaglutide
5. Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., … & Rosenstock, J. (2020). Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine, 383(9), 841-851. Retrieved from https://pubmed.ncbi.nlm.nih.gov/31952996/
6. Sattar, N., Rawshani, A., Franzén, S., Rawshani, A., Svensson, A. M., Rosengren, A., & McGuire, D. K. (2021). Age and the association of diabetes-related complications with mortality in COVID-19. Diabetes Care, 44(3), 726-733. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898914/
7. Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573908/
8. American Academy of Family Physicians. (2020). Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus. American Family Physician, 102(9), 627-628. Retrieved from https://www.aafp.org/pubs/afp/issues/2020/1115/p627.html
9. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & O’Neil, P. M. (2021). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/fulltext
10. U.S. Food and Drug Administration. (n.d.). LABEL. Retrieved from https://www.fda.gov/
11. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & O’Neil, P. M. (2021). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
12. Tan, H. C., Dampil, O. A., & Marquez, M. M. (2022). Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. Journal of the ASEAN Federation of Endocrine Societies, 37(2), 65. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758543/
13. Pharmaceutical Journal. (2021). Semaglutide effective for weight loss in non-diabetic adults. Retrieved from https://pharmaceutical-journal.com/article/news/semaglutide-effective-for-weight-loss-in-non-diabetic-adults-research-suggests
14. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., … & O’Neil, P. M. (2021). Once-daily semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989-1002. Retrieved from https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
15. Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., … & Garvey, W. T. (2023). Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Retrieved from https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01185-6/fulltext
16. Rosenstock, J., Bajaj, H. S., Janež, A., Silver, R., Begtrup, K., Hansen, M. V., … & Aroda, V. R. (2021). Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes. The Lancet. Retrieved from https://www.frontiersin.org/articles/10.3389/fphar.2022.935823/full
17. Gao, X., Hua, X., Wang, X., Xu, W., Zhang, Y., Shi, C., & Gu, M. (2022). Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: a systematic review and meta-analysis of randomized controlled trials. Frontiers in pharmacology, 13, 935823. Retrieved from https://www.frontiersin.org/articles/10.3389/fphar.2022.935823/full

Post by:

Marcella Jiovanni

Skin Care Professional

“Marcella Jiovanni actively promotes the importance of maintaining healthy skin, she envisions the future of dermatology as moving away from pure medical, pharmacological dermatology and flowing more toward a holistic approach to wellness and skincare.”